News Releases


2016 | 2015 | 2014 | Archive
Keyword Search
 
DateTitle 
02/03/16ACADIA Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference on February 10, 2016
SAN DIEGO--(BUSINESS WIRE)--Feb. 3, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, at 8:00 a.m. Eastern Time in New York City. A live we... 
Printer Friendly Version
01/29/16ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID™ (Pimavanserin) for the Treatment of Parkinson’s Disease Psychosis
Advisory Committee Meeting Scheduled for March 29, 2016 SAN DIEGO--(BUSINESS WIRE)--Jan. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review ... 
Printer Friendly Version
01/25/16ACADIA Pharmaceuticals Appoints James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer
SAN DIEGO--(BUSINESS WIRE)--Jan. 25, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the appointment of James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer. Dr. Owen will be responsible for evolving and executing t... 
Printer Friendly Version
01/11/16ACADIA Pharmaceuticals Appoints Jim Daly to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Jan. 11, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced Jim Daly has joined its Board of Directors. Mr. Daly is a biopharmaceutical executive with 30 years of experience leading U.S. and global businesses. “Jim brings ex... 
Printer Friendly Version
01/07/16ACADIA Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 12, 2016
SAN DIEGO--(BUSINESS WIRE)--Jan. 7, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it will present at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016, at 11:30 a.m. Pacific Time in San Francisco. A live webcast of ACAD... 
Printer Friendly Version
01/06/16ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--Jan. 6, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the pricing of an underwritten public offering of 10,344,827 shares of its common stock, offered at a price to the public of $29.00 per share. The gross proceeds from this offering to AC... 
Printer Friendly Version
01/05/16ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--Jan. 5, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it intends to offer and sell, subject to market and other conditions, $300,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to ... 
Printer Friendly Version